EU4Health: https://health.ec.europa.eu/funding/eu4health-programme-2021-2027-vision-healthier-european-union_en
EU4Health is an ambitious EU health program for the years 2021-2027. Its primary goal is to bolster the resilience of Europe’s health systems and to spur innovation in the health sector. The program has a budget of €5.3 billion, making it one of the largest health budgets in the history of the European Union.
Key objectives include:
– Strengthening health systems so that they can face epidemics and other long-term challenges.
– Supporting global commitments and protecting citizens from serious cross-border health threats.
– Making medicines and medical devices available and affordable, and fostering innovation.
[1] Real-World Data (RWD) and Real-World Evidence (RWE):
– RWD refers to data that are collected outside of conventional clinical trials. This includes electronic health records (EHRs), claims and billing activities, product and disease registries, and patient-related activities in smartphones and wearables.
– RWE is the evidence derived from RWD through the analysis of these real-world outcomes. RWE can provide insights into medication safety and effectiveness, treatment guidelines, and health technology assessment (HTA).
[2] Context of RWD and RWE in EU4Health: The EU recognizes the potential of RWD and RWE to bring about significant changes in healthcare decisions. By tapping into the vast amount of data generated daily in healthcare settings, decision-makers can:
– Understand the real-world effectiveness of treatments.
– Inform regulatory and reimbursement decisions.
– Understand disease patterns and trends.
[3] EU RWD Collection and RWE Generation Action Plan: This action plan represents a strategic effort to harness the power of RWD and RWE. Some of its goals and activities may include:
– Standardizing the collection and use of RWD across EU member states.
– Collaborating with stakeholders to ensure the quality and reliability of RWE.
– Building infrastructures that support data sharing and analytics.
– Training professionals in the methodologies of RWE.
It’s worth noting that as the landscape of RWD and RWE evolves, so too will the EU’s strategies and policies. The collaboration between healthcare professionals, policymakers, patients, and other stakeholders will be crucial in harnessing the full potential of RWD and RWE in the EU4Health framework.
Share this story...
Real World Evidence (RWE) 201 – Beyond Clinical Trials: Health Canada’s Commitment to Real World Evidence
RWE 201 - Beyond Clinical Trials: Health Canada's Commitment to Real World Evidence Health Canada is dedicated to enhancing drug accessibility, affordability, and correct usage within the country. To [...]
Real World Evidence (RWE) 201 – A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA
RWE 201 - A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA Non-interventional studies are different from randomized controlled trials (RCTs). Instead of actively intervening in a [...]
Real World Evidence (RWE) 201 – FDA’s Advancing RWE Program
RWE 201 - FDA's Advancing RWE Program Real-world evidence is transforming the regulatory landscape, enabling the FDA to make informed decisions based on robust data from real-world settings. [...]
Real World Evidence (RWE) 201 – FDA’s RWE Considerations Draft Guidance
RWE 201 - FDA's RWE Considerations Draft Guidance The 21st Century Cures Act, signed into law in 2016, mandated the FDA to establish a framework for the evaluation of [...]
Real World Evidence 201 – FDAs RWE Framework
RWE 201 - FDAs RWE Framework Real World Evidence (RWE) 201 – FDAs RWE Framework RWE 201: https://rwr-regs.com/rwe-201/ The FDA's Real-World Evidence (RWE) Program framework, established under the [...]
Real World Evidence 201 – The 21st Century Cures Act
RWE 201 - The 21st Century Cures Act The 21st Century Cures Act (CURES 1.0), signed into law in the U.S. in December 2016, aimed to accelerate [...]







